12:00 AM
May 28, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

EP-100: Phase II started

Esperance began an open-label, U.S. Phase II trial (ESP2011-002) to compare an IV infusion of EP-100 twice weekly for the first 3 weeks of a 4-week cycle for up to...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >